Maciej Bryl

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Combination Therapy

Tyrosine Kinase

Ejection Fraction

Top Venues

Cancer immunology, immunotherapy : CII

Journal of personalized medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Niels Reinmuth, Oscar Juan Vidal, Dariusz Mirosław Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, Ihor Vynnychenko, Jon Armstrong, Tapashi Dalvi, Mingchao Xie, Sonia Iyer, Yashaswi Shrestha, Haiyi Jiang, Igor Bondarenko
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Piotr Gabryel, Piotr Skrzypczak, Magdalena Roszak, Alessio Campisi, Dominika Zielińska, Maciej Bryl, Katarzyna Stencel, Cezary Piwkowski
Influencing Factors on the Quality of Lymph Node Dissection for Stage IA Non-Small Cell Lung Cancer: A Retrospective Nationwide Cohort Study. Cancers 16 (2) (2024)
Piotr Gabryel, Piotr Skrzypczak, Magdalena Roszak, Alessio Campisi, Dominika Zielińska, Maciej Bryl, Katarzyna Stencel, Cezary Piwkowski
Influencing Factors on the Quality of Lymph Node Dissection for Stage IA Non-Small Cell Lung Cancer: A Retrospective Nationwide Cohort Study. Cancers 16 (2) (2024)
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Franciszek K Główka
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. Cancer immunology, immunotherapy : CII (2023)
Adam Płużański, Maciej Bryl, Izabela Chmielewska, Grzegorz Czyzewicz, Joanna Luboch-Kowal, Anna Wrona, Agnieszka Samborska, Maciej Krzakowski
Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study. Cancers 15 (5) (2023)
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Franciszek K Główka
Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. Cancer immunology, immunotherapy : CII (2023)
Adam Płużański, Maciej Bryl, Izabela Chmielewska, Grzegorz Czyzewicz, Joanna Luboch-Kowal, Anna Wrona, Agnieszka Samborska, Maciej Krzakowski
Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study. Cancers 15 (5) (2023)
Marek Konkol, Maciej Bryl, Marek Fechner, Krzysztof Matuszewski, Paweł Śniatała, Piotr Milecki
Normal Lung Tissue CT Density Changes after Volumetric-Arc Radiotherapy (VMAT) for Lung Cancer. Journal of personalized medicine 12 (3) (2022)
Anna Siemiątkowska, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Aleksander Barinow-Wojewódzki, Franciszek K Główka
Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers 13 (15) (2021)